Trial Profile
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Genentech
- 05 Jun 2021 Results of post hoc analysis (n=260) Patients with Moderate to Severe Active Systemic Lupus Erythematosus Enrolled in a 48 Week Phase II Randomized Clinical Trial presented at the 22nd Annual Congress of the European League Against Rheumatism
- 27 May 2021 Results published in the Arthritis and Rheumatology
- 06 Jun 2020 Results of post hoc subgroup analysis presented at the 21st Annual Congress of the European League Against Rheumatism